Switch to:

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 4/10

vs
industry
vs
history
Cash to Debt 0.18
MNK's Cash to Debt is ranked higher than
53% of the 926 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.48 vs. MNK: 0.18 )
MNK' s 10-Year Cash to Debt Range
Min: 0.18   Max: No Debt
Current: 0.18

Equity to Asset 0.39
MNK's Equity to Asset is ranked higher than
55% of the 833 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.59 vs. MNK: 0.39 )
MNK' s 10-Year Equity to Asset Range
Min: 0.35   Max: 0.39
Current: 0.39

0.35
0.39
Z-Score: 1.16
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 3/10

vs
industry
vs
history
Operating margin (%) -11.18
MNK's Operating margin (%) is ranked higher than
57% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 10.10 vs. MNK: -11.18 )
MNK' s 10-Year Operating margin (%) Range
Min: -11.18   Max: 11.91
Current: -11.18

-11.18
11.91
Net-margin (%) -12.57
MNK's Net-margin (%) is ranked higher than
57% of the 875 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 7.05 vs. MNK: -12.57 )
MNK' s 10-Year Net-margin (%) Range
Min: -12.57   Max: 7.45
Current: -12.57

-12.57
7.45
ROE (%) -15.67
MNK's ROE (%) is ranked higher than
57% of the 895 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 6.83 vs. MNK: -15.67 )
MNK' s 10-Year ROE (%) Range
Min: -10.28   Max: 9.37
Current: -15.67

-10.28
9.37
ROA (%) -5.17
MNK's ROA (%) is ranked higher than
60% of the 930 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.82 vs. MNK: -5.17 )
MNK' s 10-Year ROA (%) Range
Min: -3.89   Max: 3.31
Current: -5.17

-3.89
3.31
ROC (Joel Greenblatt) (%) -18.02
MNK's ROC (Joel Greenblatt) (%) is ranked higher than
60% of the 925 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 14.02 vs. MNK: -18.02 )
MNK' s 10-Year ROC (Joel Greenblatt) (%) Range
Min: -19.35   Max: 19.2
Current: -18.02

-19.35
19.2
» MNK's 10-Y Financials

Financials


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow

» Details

Guru Trades

Q1 2014

MNK Guru Trades in Q1 2014

Paul Tudor Jones 360,100 sh (New)
Steven Cohen 557,066 sh (New)
Pioneer Investments 121,494 sh (New)
Jean-Marie Eveillard 187 sh (unchged)
Vanguard Health Care Fund Sold Out
Eric Mindich Sold Out
John Paulson 5,636,800 sh (-0.06%)
Jana Partners 3,267,691 sh (-1.35%)
Jim Simons 254,100 sh (-9.22%)
Chuck Royce 178,505 sh (-55.6%)
» More
Q2 2014

MNK Guru Trades in Q2 2014

Paul Singer 916,000 sh (New)
Richard Perry 134,322 sh (New)
Chase Coleman 729,373 sh (New)
Mario Gabelli 2,656 sh (New)
Jana Partners 5,725,711 sh (+75.22%)
John Paulson 6,724,800 sh (+19.3%)
Jean-Marie Eveillard 187 sh (unchged)
Chuck Royce Sold Out
Pioneer Investments 120,663 sh (-0.68%)
Jim Simons 238,900 sh (-5.98%)
Paul Tudor Jones 308,900 sh (-14.22%)
» More
Q3 2014

MNK Guru Trades in Q3 2014

Chuck Royce 23,407 sh (New)
Steven Cohen 31,900 sh (New)
Joel Greenblatt 115,541 sh (New)
John Hussman 67,275 sh (New)
Richard Perry 1,150,000 sh (+756.15%)
Mario Gabelli 7,134 sh (+168.6%)
Jim Simons 359,502 sh (+50.48%)
John Paulson 9,000,000 sh (+33.83%)
Pioneer Investments 120,582 sh (unchged)
Jean-Marie Eveillard 187 sh (unchged)
Chase Coleman Sold Out
Paul Singer Sold Out
Jana Partners Sold Out
Paul Tudor Jones 24,849 sh (-91.96%)
» More
Q4 2014

MNK Guru Trades in Q4 2014

Louis Moore Bacon 14,363 sh (New)
RS Investment Management 34,500 sh (New)
Pioneer Investments 1,418,356 sh (+1076.26%)
Mario Gabelli 7,922 sh (+11.05%)
John Paulson 9,012,293 sh (+0.14%)
Jean-Marie Eveillard 187 sh (unchged)
John Hussman 67,275 sh (unchged)
Richard Perry Sold Out
Chuck Royce Sold Out
Steven Cohen 31,700 sh (-0.63%)
Joel Greenblatt 110,019 sh (-4.78%)
Jim Simons 117,502 sh (-67.32%)
Paul Tudor Jones 2,184 sh (-91.21%)
» More
» Details

Insider Trades

Latest Guru Trades with MNK

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

GuruDate Trades Impact to Portfolio Price Range * (?) Current Price Change from Average Current Shares
Richard Perry 2014-12-31 Sold Out 3.8%$83.19 - $99.73 $ 116.1926%0
Richard Perry 2014-09-30 Add 756.15%3.36%$68.12 - $90 $ 116.1949%1150000
John Paulson 2014-09-30 Add 33.83%0.86%$68.12 - $90 $ 116.1949%9000000
John Hussman 2014-09-30 New Buy0.52%$68.12 - $90 $ 116.1949%67275
Joel Greenblatt 2014-09-30 New Buy0.1%$68.12 - $90 $ 116.1949%115541
Mario Gabelli 2014-09-30 Add 168.6%$68.12 - $90 $ 116.1949%7134
John Paulson 2014-06-30 Add 19.3%0.37%$60.28 - $82.7 $ 116.1961%6724800
Richard Perry 2014-06-30 New Buy0.3%$60.28 - $82.7 $ 116.1961%134322
Mario Gabelli 2014-06-30 New Buy$60.28 - $82.7 $ 116.1961%2656
Vanguard Health Care Fund 2014-03-31 Sold Out 0.08%$50.7 - $72.81 $ 116.1986%0
Premium More recent guru trades are included for Premium Members only!!
Premium More recent guru trades are included for USA Subscribe Members only!!
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Ratios

vs
industry
vs
history
Forward P/E 27.25
MNK's Forward P/E is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 58.14 vs. MNK: 27.25 )
N/A
P/B 1.40
MNK's P/B is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.57 vs. MNK: 1.40 )
MNK' s 10-Year P/B Range
Min: 1   Max: 3.59
Current: 1.4

1
3.59
P/S 3.20
MNK's P/S is ranked higher than
78% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 4.01 vs. MNK: 3.20 )
MNK' s 10-Year P/S Range
Min: 1.11   Max: 3.2
Current: 3.2

1.11
3.2
PFCF 35.90
MNK's PFCF is ranked higher than
92% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 0.00 vs. MNK: 35.90 )
MNK' s 10-Year PFCF Range
Min: 21.68   Max: 45.83
Current: 35.9

21.68
45.83
POCF 22.50
MNK's POCF is ranked higher than
87% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 36.53 vs. MNK: 22.50 )
MNK' s 10-Year POCF Range
Min: 12.38   Max: 45.83
Current: 22.5

12.38
45.83
EV-to-EBIT -55.10
MNK's EV-to-EBIT is ranked higher than
60% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 35.09 vs. MNK: -55.10 )
MNK' s 10-Year EV-to-EBIT Range
Min: -47.3   Max: 52.1
Current: -55.1

-47.3
52.1
Current Ratio 2.29
MNK's Current Ratio is ranked higher than
74% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 2.36 vs. MNK: 2.29 )
MNK' s 10-Year Current Ratio Range
Min: 2.29   Max: 2.31
Current: 2.29

2.29
2.31
Quick Ratio 1.85
MNK's Quick Ratio is ranked higher than
76% of the 900 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.83 vs. MNK: 1.85 )
MNK' s 10-Year Quick Ratio Range
Min: 1.64   Max: 1.85
Current: 1.85

1.64
1.85
Days Inventory 113.08
MNK's Days Inventory is ranked higher than
83% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 153.90 vs. MNK: 113.08 )
MNK' s 10-Year Days Inventory Range
Min: 62.36   Max: 109.13
Current: 113.08

62.36
109.13
Days Sales Outstanding 78.39
MNK's Days Sales Outstanding is ranked higher than
80% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 94.97 vs. MNK: 78.39 )
MNK' s 10-Year Days Sales Outstanding Range
Min: 66.36   Max: 78.39
Current: 78.39

66.36
78.39

Valuation & Return

vs
industry
vs
history
Price/Median PS Value 1.60
MNK's Price/Median PS Value is ranked higher than
64% of the 967 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 1.36 vs. MNK: 1.60 )
MNK' s 10-Year Price/Median PS Value Range
Min: 0.64   Max: 1.28
Current: 1.6

0.64
1.28
Earnings Yield (Greenblatt) -1.80
MNK's Earnings Yield (Greenblatt) is ranked higher than
61% of the 927 Companies
in the Global Drug Manufacturers - Specialty & Generic industry.

( Industry Median: 3.10 vs. MNK: -1.80 )
MNK' s 10-Year Earnings Yield (Greenblatt) Range
Min: -1.8   Max: 5
Current: -1.8

-1.8
5

Analyst Estimate

Sep15 Sep16 Sep17
Revenue(Mil) 3,632 3,775 4,035
EPS($) 7.31 4.21 9.14
EPS without NRI($) 7.31 4.21 9.14

Business Description

Industry: Drug Manufacturers » Drug Manufacturers - Specialty & Generic
Compare: » details
Traded in other countries:MCD.Germany,
Mallinckrodt PLC develops, manufactures, markets and distributes specialty pharmaceutical products and diagnostic imaging agents. Its specialty pharmaceutical products are sold to wholesalers and retail drugstore chains. The Company's Specialty Pharmaceuticals segment includes branded and generic drugs, and the Global Medical Imaging segment includes contrast media and nuclear imaging agents. The Company's products include Intrathecal Product used in the management of cerebral or spinal spasticity. The Company's nonsteroidal anti-inflammatory drug (NSAID) portfolio helps address the signs and symptoms of painful condition. PENNSAID, is a nonsteroidal anti-inflammatory drug (NSAID) indicated for the treatment of signs and symptoms of osteoarthritis of the knee(s). The Opioid products include EXALGO. It is an Extended-Release Tablets indicated for the management of moderate to severe pain in opioid tolerant patients requiring continuous, around-the-clock opioid analgesia for an extended period of time. The Central Nervous Systems' products include Anafranil, indicated for the treatment of obsessions and compulsions in patients with Obsessive-Compulsive Disorder (OCD). The Global Medical Imaging products includes Optisuite, Optibolus Bolus Shaping Software, Ready-Box, Ultra-Technekow DTE Generator, Octreoscan, and Technescan MAG3.
» More Articles for MNK

Headlines

Articles On GuruFocus.com
Paulson Bets Again On Mallinckrodt Aug 07 2014 
Dumb Investment of the Week: Mallinckrodt PLC Jul 17 2014 
Mallinckrodt Acquired San Diego Pharma and Much More Mar 21 2014 
Can Malllinckrodt Keep on Crushing Expectations? Mar 19 2014 
Should You Buy Actavis? Mar 18 2014 
Weekly 3-Year Low Highlight: EW, NUAN, MNK, CROX, IRDM Nov 03 2013 


More From Other Websites
Mallinckrodt to Present at Barclays Conference March 11 Mar 04 2015
Mallinckrodt to Present at Barclays Conference March 11 Mar 04 2015
Actavis' Xydalba Granted Marketing Authorisation in Europe - Analyst Blog Mar 03 2015
Mallinckrodt PLC (MNK), Pfizer Inc. (PFE): Healthcor Management’s Top 5 Health Stocks Mar 02 2015
Why Mallinckrodt (MNK) Could Beat Earnings Estimates Again - Tale of the Tape Feb 27 2015
Five Top-Rated Medical Stocks To Keep Monitoring Feb 23 2015
10 Stocks Billionaire John Paulson Loves for 2015: Allergan, Time Warner Cable and More Feb 19 2015
Actavis Tops Views, Announces Name Change To Allergan Feb 18 2015
European Optimism Defies Greece, Ukraine And GDP Views Feb 13 2015
Mallinckrodt Plc (MNK): New Analyst Report from Zacks Equity Research - Zacks Equity Research Report Feb 13 2015
MALLINCKRODT PLC Financials Feb 10 2015
Mallinckrodt Earnings Soar on Acquisitions Feb 03 2015
Akorn, Actavis Near Buy Points Amid Market Turbulence Feb 03 2015
Mylan to Buy Famy Care Businesses, Boost Women's Health - Analyst Blog Feb 03 2015
Mallinckrodt's Mixed Q1 Stokes Analyst Worries Feb 03 2015
Mallinckrodt (MNK) Earnings Report: Q1 2015 Conference Call Transcript Feb 03 2015
Mallinckrodt Beats on Q1 Earnings, Sales Miss Estimates - Analyst Blog Feb 03 2015
Mallinckrodt Beats on Q1 Earnings Boosted by Acquisitions - Tale of the Tape Feb 03 2015
Mallinckrodt Plc Earnings Call scheduled for 8:30 am ET today Feb 03 2015
Mallinckrodt beats 1Q profit forecasts Feb 03 2015

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)
Free 7-day Trial
FEEDBACK